Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Xencor Inc (Xencor) is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. The company product pipeline includes XmAb819 which treats renal cell carcinoma; XmAb541 for ovarian cancer; XmAb808 targets oncology; XmAb942 for inflammatory bowel disease; Plamotamab which targets multi-drug resistant rheumatoid arthritis; and XmAb657 for autoimmune diseases. It also offers partnered programs such as JNJ-1493 for B-cell tumors; JNJ-9401 targets prostate cancer; ASP2138 treats gastric and gastroesophageal junction adenocarcinoma and pancreatic adenocarcinoma; among others. Xencor is headquartered in Pasadena, California, the US.
Headquarters
United States of America
Address
Suite 200, 465 North Halstead Street, Pasadena, California, 91107
Website
xencor.com
Telephone
1 626 3055900
No of Employees
260
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
XNCR (NASD)
Revenue (2024)
$125.6M
13.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
60.5%
(2024 vs 2023)
Market Cap*
$1.1B
Net Profit Margin (2024)
XYZ
65.2%
(2024 vs 2023)
* As of and is in US$
Xencor Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | XmAb |
| XmAb819: Renal Cell Carcinoma | Ultomiris |
| XmAb541: Ovarian Cancer | Monjuvi |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Xencor Inc | Pfizer Inc | AstraZeneca Plc | Bristol-Myers Squibb Co | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | United States of America | United States of America |
| City | Pasadena | New York City | Cambridge | Princeton | Thousand Oaks |
| State/Province | California | New York | Cambridgeshire | New Jersey | California |
| No. of Employees | 260 | 75,000 | 96,100 | 32,500 | 31,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Bassil I. Dahiyat, Ph.D. | Director; President; Chief Executive Officer | Executive Board | 2005 | 54 |
| Bart Jan Cornelissen | Senior Vice President; Chief Financial Officer | Senior Management | 2024 | 47 |
| Dane Leone | Executive Vice President; Chief Strategy Officer | Senior Management | 2024 | - |
| John R. Desjarlais, Ph.D. | Executive Vice President - Research; Chief Scientific Officer | Senior Management | 2023 | 60 |
| Celia Eckert | Secretary; General Counsel; Senior Vice President | Senior Management | 2019 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer